CareDx Acquires Naveris, Extends Leadership into High-Growth Specialty Oncology

By Karen Roman

CareDx, Inc. (Nasdaq: CDNA) said it completed the acquisition of Naveris, which includes its leading product, NavDx, a blood-based test for viral-mediated cancer detection including human papillomavirus, and associated head and neck and anal cancers.

NavDx is the first and only Medicare-covered test for HPV-driven head and neck and anal cancer molecular residual disease surveillance, the company stated. CareDx also has a portfolio of precision diagnostic testing services directed to a U.S. market estimated to exceed $12 billion, it said.

Never Miss our Weekly Highlights HERE

“CareDx wins by commercializing category-leading, repeat molecular biomarker testing for patients with a high burden of disease — that’s our growth model,” said John Hanna, CareDx President and CEO. “NavDx fits that model precisely. We believe we have the platform and the focus to scale it, and we expect it to be a meaningful contributor to CareDx’s growth from day one.”

READ MORE

SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation

Contact:

The post CareDx Acquires Naveris, Extends Leadership into High-Growth Specialty Oncology appeared first on ExecEdge.